Biomarkers of tolerance in response to allergen immunotherapy
Durham, S.R.; Scadding, G.W.; Phippard, D.; Wurtzen, P.A.; Shamji, M.H.
Arbeiten aus dem Paul-Ehrlich-Institut Langen/Hessen 97: 75-81
2013
PMID: 24912316 Document Number: 11186
Subcutaneous allergen immunotherapy is effective in adults and children with allergic rhinitis and mild asthma with a limited spectrum of allergies. It is particularly effective in seasonal pollinosis and prolonged treatment has been shown to induce disease remission for at least several years after discontinuation of treatment. The sublingual route is an effective and safer alternative that also has longterm effects in seasonal disease whereas evidence for efficacy in perennial rhinitis, particularly in children, is far less convincing. The modern era of recombinant allergens is likely to provide standardised reagents that have potential to pre-select individuals for immunotherapy based on their profile of allergen sensitivities and to monitor serum antibodies to individual allergen components. This approach is highly rational and whether or not the use of recombinant 'natural' or mutant allergens will translate into more effective preselection and/or correlate with efficacy is yet to be determined.
Document emailed within 1 workday
